Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KRAS G12D siRNA for Metastatic Pancreas Cancer Patients Harboring KRAS G12D Mutation
The purpose of this phase I study is to evaluate the safety and feasibility of KRAS G12D siRNA (iExosomes) in patients with metastatic pancreatic cancer with KRAS G12D mutation.
Study ID: 2018-0126
Trial Phase: Phase I
Trial Sponsor: M.D. Anderson Cancer Center
Therapies Used in This Trial: iExosomes